Thaysen announced, “We expect organic revenue growth of 2% to 4% in 2026, excluding China, with overall demand similar to what we saw in the second half of 2025. Clinical consumables grew ...
Hosted on MSN
Illumina outlines 2026 revenue guidance of $4.5B–$4.6B while advancing clinical growth and multiomics strategy
CEO Jacob Thaysen announced that Q4 results "exceeded expectations, capped off with 20% growth in our clinical consumables revenue ex-China, reflecting execution across the organization as we closed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results